Home Newsfeeds Raymond James Reinstates Market Perform on Qualcomm

Raymond James Reinstates Market Perform on Qualcomm

Raymond James analyst Srini Pajjuri reinstates Qualcomm (NASDAQ:QCOM) with a Market Perform.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Raymond James analyst Srini Pajjuri reinstates Qualcomm (NASDAQ:QCOM) with a Market Perform.

Paya Holdings Q2 Adj. EPS $0.10 Beats $0.09 Estimate, Sales $72.50M Beat $69.90M Estimate

By Bill Haddad

August 5, 6:07 AM

Paya Holdings (NASDAQ:PAYA) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.09 by 11.11 percent. This is a 9.09 percent decrease over earnings of $0.11 per share from the

PAYA

EPOW Announces Revenue Growth Of 1,718% For First 3 Months Of 2023, Chairman Purchases 20,000 Shares Of Stock At An Average Price Of $2.78; Q1 2023 Revenue $8M Vs $440,000 YoY

By Happy Mohamed

April 14, 9:47 AM

Sunrise New Energy Co., Ltd. ("Sunrise", the "Company", "we" or "our") (NASDAQ:EPOW), today announced that the revenues for the first 3 months of 2023, ending March 31st,

EPOW

InflaRx’s Stock Gains Following FDA Fast Track Status To Skin Disease Drug

By Ragothaman Srinivasan

July 6, 8:53 AM

The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).

IFRX

Dogecoin To Jump 125% Amid Crypto Slide? Analyst Says ‘Maybe I’m Crazy’ But Sets Sight On This Level

By Mehab Qureshi

August 22, 5:37 AM

A pseudonymous analyst is making bold predictions about the future of Dogecoin (CRYPTO: DOGE), foreseeing a surge of more than 125%. What Happened: Kaleo on Monday said, “Maybe I’m crazy, but I’m watching for something like this.”

$DOGE

Raymond James Reinstates Market Perform on Qualcomm

Related Posts

Paya Holdings Q2 Adj. EPS $0.10 Beats $0.09 Estimate, Sales $72.50M Beat $69.90M Estimate

EPOW Announces Revenue Growth Of 1,718% For First 3 Months Of 2023, Chairman Purchases 20,000 Shares Of Stock At An Average Price Of $2.78; Q1 2023 Revenue $8M Vs $440,000 YoY

InflaRx’s Stock Gains Following FDA Fast Track Status To Skin Disease Drug

Dogecoin To Jump 125% Amid Crypto Slide? Analyst Says ‘Maybe I’m Crazy’ But Sets Sight On This Level